Fortrea Holdings Inc. (FTRE)
NASDAQ: FTRE · Real-Time Price · USD
19.85
-0.58 (-2.84%)
Sep 23, 2026, 3:03 PM EDT - Market open
Fortrea Holdings Employees
Fortrea Holdings had 14,000 employees as of June 30, 2026. The number of employees decreased by 500 or -3.45% compared to the same quarter last year.
Employees
14,000
Change
-500
Growth
-3.45%
Revenue / Employee
$191,179
Profits / Employee
-$6,086
Market Cap
1.89B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 14,000 | -500 | -3.45% | 14,000 | 0 |
| Mar 31, 2026 | 14,000 | -1,000 | -6.67% | 14,000 | 0 |
| Dec 31, 2025 | 14,300 | -1,820 | -11.29% | 13,871 | 429 |
| Sep 30, 2025 | 14,500 | -1,000 | -6.45% | 14,500 | 0 |
| Jun 30, 2025 | 14,500 | -1,500 | -9.38% | 14,500 | 0 |
| Mar 31, 2025 | 15,000 | -1,000 | -6.25% | 15,000 | 0 |
| Dec 31, 2024 | 16,120 | -1,880 | -10.44% | 15,500 | 620 |
| Sep 30, 2024 | 15,500 | -3,500 | -18.42% | 15,500 | 0 |
| Jun 30, 2024 | 16,000 | -3,000 | -15.79% | 16,000 | 0 |
| Mar 31, 2024 | 16,000 | -2,000 | -11.11% | 16,000 | 0 |
| Dec 31, 2023 | 18,000 | 0 | - | 17,460 | 540 |
| Sep 30, 2023 | 19,000 | 1,000 | 5.56% | 19,000 | 0 |
| Jun 30, 2023 | 19,000 | - | - | 19,000 | 0 |
| Mar 31, 2023 | 18,000 | - | - | 17,370 | 630 |
| Dec 31, 2022 | 18,000 | - | - | 17,370 | 630 |
Related Stocks
| Company Name | Employees |
|---|---|
| Vir Biotechnology | 367 |
| Xencor | 260 |
| Zymeworks | 231 |
| Lakefront Biotherapeutics NV | 196 |
| Stoke Therapeutics | 170 |
| Mesoblast | 108 |
| Tyra Biosciences | 87 |
| Rapport Therapeutics | 84 |
FTRE News
- 8 days ago - Fortrea Holdings Transcript: 2026 Global Healthcare Conference - Transcripts
- 12 days ago - Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 13 days ago - Fortrea to Participate in September Investor Conferences - GlobeNewsWire
- 21 days ago - Fortrea to buy Worldwide Clinical Trials Early Phase Services division for $45M - TheFly
- 21 days ago - Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials - GlobeNewsWire
- 7 weeks ago - Fortrea price target raised to $23 from $19 at TD Cowen - TheFly
- 7 weeks ago - Fortrea price target raised to $22 from $20 at Citi - TheFly
- 7 weeks ago - Fortrea price target raised to $20 from $18 at Deutsche Bank - TheFly